World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
53889
World Ranking
5276
National Ranking
2849

Gary K. Schwartz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gary K. Schwartz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 624 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gary K. Schwartz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gary K. Schwartz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gary K. Schwartz is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a notable focus on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Hematology as subfields.

The scientist's work covers several important topics within cancer research and treatment, including:

  • Sarcoma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • Ocular Oncology and Treatments
  • Multiple Myeloma Research and Treatments
  • Immunotherapy and Immune Responses

Some recent papers featuring Gary K. Schwartz include:

  • Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium (2021) in Annals of Oncology
  • Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) (2020) in Clinical Trials
  • The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (2020) in JNCI Journal of the National Cancer Institute
  • Dissecting the treatment-naive ecosystem of human melanoma brain metastasis (2022) in Cell
  • Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial (2024) in The Lancet

Gary K. Schwartz frequently collaborates with several researchers, including:

  • Matthew Ingham
  • Richard D. Carvajal
  • Steven Attia
  • Suzanne George
  • Brian Andrew Van Tine

The leading venues for their publications are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Cureus
  • Physician leadership journal

In addition to journal articles, Gary K. Schwartz has contributed to book publications. One known work is Rembrandt Seen Through Jewish Eyes, published in 2023 by Amsterdam University Press.

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Tumour exosome integrins determine organotropic metastasis

    Ayuko Hoshino;Bruno Costa-Silva;Tang-Long Shen;Goncalo Rodrigues

  • Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

    Ki Young Chung;Jinru Shia;Nancy E. Kemeny;Manish Shah

  • KIT as a therapeutic target in metastatic melanoma

    Richard D. Carvajal;Cristina R. Antonescu;Jedd D. Wolchok;Paul B. Chapman

  • Targeting the Cell Cycle: A New Approach to Cancer Therapy

    Gary K. Schwartz;Manish A. Shah

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

    Jordi Barretina;Barry S Taylor;Barry S Taylor;Shantanu Banerji;Shantanu Banerji;Alexis H Ramos;Alexis H Ramos

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

    Robert G. Maki;David R. D'Adamo;Mary L. Keohan;Michael Saulle

  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

    William D Tap;William D Tap;Robin L Jones;Robin L Jones;Brian A Van Tine;Bartosz Chmielowski

  • Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

    Sandra P D'Angelo;Sandra P D'Angelo;Michelle R Mahoney;Brian A Van Tine;James Atkins

  • Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor

  • Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

    Manish A. Shah;Gary K. Schwartz

  • Replacement of Fhit in cancer cells suppresses tumorigenicity

    Zurab Siprashvili;Gabriella Sozzi;Larry D. Barnes;Peter McCue

  • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival

    Geoffrey Y. Ku;Jianda Yuan;David B. Page;Sebastian E. A. Schroeder

  • AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

    Sonya D Zabludoff;Chun Deng;Michael R Grondine;Adam M Sheehy

  • Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

    Mark A. Dickson;William D. Tap;Mary Louise Keohan;Sandra P. D'Angelo

  • Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

    Richard D. Carvajal;Jeffrey A. Sosman;Jorge Fernando Quevedo;Mohammed M. Milhem

  • Sorafenib for Advanced and Refractory Desmoid Tumors.

    Mrinal M. Gounder;Michelle R. Mahoney;Brian A. Van Tine;Vinod Ravi

  • Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

    Keith T. Flaherty;Patricia M. LoRusso;Angela DeMichele;Vandana G. Abramson

Frequent Co-Authors

Richard D. Carvajal
Richard D. Carvajal Columbia University
David P. Kelsen
David P. Kelsen Memorial Sloan Kettering Cancer Center
Samuel Singer
Samuel Singer Memorial Sloan Kettering Cancer Center
Robert G. Maki
Robert G. Maki University of Pennsylvania
Manish A. Shah
Manish A. Shah Cornell University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Paul B. Chapman
Paul B. Chapman Memorial Sloan Kettering Cancer Center
Mithat Gonen
Mithat Gonen Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers beyond medical school, several flexible online degree options are available. Many nursing professionals look for programs that allow them to advance their education while balancing work and personal commitments. For instance, rn to bsn online no clinicals programs enable registered nurses to earn a bachelor’s degree without the requirement of in-person clinical hours, making it easier to fit studies around a busy schedule.

Those aiming for leadership roles might consider online dnp programs, which allow students to attain the highest level of nursing practice. Similarly, there are easy dnp programs offering streamlined coursework for qualified professionals seeking career progression.

If you’re just starting in healthcare, there are also 9 month lpn program options that provide a fast track into practical nursing. Exploring these related online degrees and pathways can help you choose an educational journey that fits your goals and lifestyle.

Best Scientists Citing Gary K. Schwartz

Trending Scientists

Recently Published Articles